Enzyme-Linked Lipid Nanocarriers for Coping Pseudomonal Pulmonary Infection. Would Nanocarriers Complement Biofilm Disruption or Pave Its Road?

Int J Nanomedicine. 2024 Apr 29:19:3861-3890. doi: 10.2147/IJN.S445955. eCollection 2024.

Abstract

Introduction: Cystic fibrosis (CF) is associated with pulmonary Pseudomonas aeruginosa infections persistent to antibiotics.

Methods: To eradicate pseudomonal biofilms, solid lipid nanoparticles (SLNs) loaded with quorum-sensing-inhibitor (QSI, disrupting bacterial crosstalk), coated with chitosan (CS, improving internalization) and immobilized with alginate lyase (AL, destroying alginate biofilms) were developed.

Results: SLNs (140-205 nm) showed prolonged release of QSI with no sign of acute toxicity to A549 and Calu-3 cells. The CS coating improved uptake, whereas immobilized-AL ensured >1.5-fold higher uptake and doubled SLN diffusion across the artificial biofilm sputum model. Respirable microparticles comprising SLNs in carbohydrate matrix elicited aerodynamic diameters MMAD (3.54, 2.48 µm) and fine-particle-fraction FPF (65, 48%) for anionic and cationic SLNs, respectively. The antimicrobial and/or antibiofilm activity of SLNs was explored in Pseudomonas aeruginosa reference mucoid/nonmucoid strains as well as clinical isolates. The full growth inhibition of planktonic bacteria was dependent on SLN type, concentration, growth medium, and strain. OD measurements and live/dead staining proved that anionic SLNs efficiently ceased biofilm formation and eradicated established biofilms, whereas cationic SLNs unexpectedly promoted biofilm progression. AL immobilization increased biofilm vulnerability; instead, CS coating increased biofilm formation confirmed by 3D-time lapse confocal imaging. Incubation of SLNs with mature biofilms of P. aeruginosa isolates increased biofilm density by an average of 1.5-fold. CLSM further confirmed the binding and uptake of the labeled SLNs in P. aeruginosa biofilms. Considerable uptake of CS-coated SLNs in non-mucoid strains could be observed presumably due to interaction of chitosan with LPS glycolipids in the outer cell membrane of P. aeruginosa.

Conclusion: The biofilm-destructive potential of QSI/SLNs/AL inhalation is promising for site-specific biofilm-targeted interventional CF therapy. Nevertheless, the intrinsic/extrinsic fundamentals of nanocarrier-biofilm interactions require further investigation.

Keywords: Pseudomonas aeruginosa; alginate lyase; chitosan; cystic fibrosis; quorum-sensing inhibitors; solid lipid nanoparticles.

MeSH terms

  • A549 Cells
  • Alginates / chemistry
  • Anti-Bacterial Agents* / chemistry
  • Anti-Bacterial Agents* / pharmacokinetics
  • Anti-Bacterial Agents* / pharmacology
  • Biofilms* / drug effects
  • Chitosan* / chemistry
  • Cystic Fibrosis / drug therapy
  • Cystic Fibrosis / microbiology
  • Drug Carriers / chemistry
  • Humans
  • Lipids / chemistry
  • Lipids / pharmacology
  • Liposomes*
  • Nanoparticles* / chemistry
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas aeruginosa* / drug effects
  • Pseudomonas aeruginosa* / physiology
  • Quorum Sensing / drug effects

Substances

  • Chitosan
  • Anti-Bacterial Agents
  • Drug Carriers
  • Lipids
  • Lipid Nanoparticles
  • Alginates
  • Liposomes